文献リスト

1) Malthaner R, Collin S, Fenlon D, et al. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database of Systematic Reviews. 2006, Issue 3. Art. No.: CD001556

2) Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in esophageal carcinoma: a meta-analysis. Lancet Oncology. 2007; 8: 226-34

3) Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008; 26: 1086-92

4) Ku GY, Ilson DH. Preoperative therapy for esophageal cancer. Gastroenterol Clin North Am. 2009; 38: 135-52

5) van Heijl M, van Lanschot JJ, Koppert LB, et al. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg. 2008; 8: 21

6) 日本食道学会, 編. 食道癌診断・治療ガイドライン. 東京: 金原出版; 2007

7) Igaki H, Kato H, Ando N, et al. A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907). ASCO Annual Meeting. 2008

8) Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N EngI J Med. 2006; 355: 202-6

9) Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCCACCORD07-FFCD 9703 trial. Proc Am Soc Clin Oncol. 2007; 25: A4510

10) Fiorica F, Cartei F, Enea M, et al. The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. Cancer Treat Rev. 2007; 33: 729-40

11) Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345: 725-30

12) Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358: 36-46

13) Combination chemotherapy with or without bevacizumab in treating patients with previously untreated stomach cancer or gastroesophageal junction cancer that can be removed by surgery. Clinicaltrials. gov. Available at http://clinicaltrials.gov/ct/show/NCT00450203

14) Randomized phase III trial of adjuvant chemotherapy or chemoradiotherapy in resectable gastric cancer (CRITICS). Clinicaltrials. gov. Available at http://clinicaltrials.gov/show/NCT00407186

15) Yoshikawa T, Sasako M, Yamamoto S, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009 Jul 30. [Epub ahead of print]

16) Fujitani K, Sasako M, Iwasaki Y, et al. A phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically respectable type 4 and large type 3 gastric cancer: JCOG0210. Proc ASCO(abstr #4609), 2007

17) Phase III trial of neoadjuvant TS-1 and CDDP for type 4 and large type 3 gastric cancer: JCOG0501. Clinicaltrials. gov. Available at http://clinicaltrials.gov/show/NCT00252161

18) Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357: 1810-20

19) 大腸癌研究会, 編. 大腸癌治療ガイドライン. 医師用2009年版. 東京: 金原出版; 2009

20) Bosset JF, Collette L, Calais G, et al. EORTC Radiotherapy Group Trial 22921: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006; 355: 1114-23

21) Mohiuddin M, Winter K, Mitchell E, et al. Radiation Therapy Oncology Group Tria1 0012: Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Tria1 0012. J Clin Oncol. 2006; 24: 650-5

22) Calvo FA, Serrano FJ, Diaz-Gonzalez JA, et al. Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation. Ann Oncol. 2006; 17: 1103-10

23) Ryan DP, Niedzwiecki D, Hollis D, et al. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol. 2006; 24: 2557-62

24) NSABP Clinical Trials Overview. Protocol R-04, a clinical trial comparing preoperative radiation therapy and capecitabine with or without oxaliplatin with preoperative radiation therapy and continuous intravenous infusion of 5-Fluorouracil with or without oxaliplatin in the treatment of patients with operable carcinoma of the rectum. http://www.nsabp.pitt.edu/R-04.asp

25) Phase II randomized study of neoadjuvant chemoradiotherapy and adjuvant chemotherapy in patients with locally advanced rectal cancer undergoing surgical resection. http://www.cancer.gov/clinicaltrials/RTOG-0247

26) Phase II study of neoadjuvant bevacizumab in combination with radiotherapy, capecitabine, and oxaliplatin followed by surgical resection and adjuvant bevacizumab in combination with fluorouracil, leucovorin calcium, and oxaliplatin in patients with locally advanced nonmetastatic rectal cancer. http://www.cancer.gov/clinicaltrials/ECOG-E3204

27) Nordlinger B. Preoperative chemotherapy with FOLFOX4 and surgery versus surgery alone for respectable liver metastases from colorectal cancer (EORTC 40983): a randomised controlled trial. Lancet. 2008; 371: 1007-16

28) Rubbia-Brandt L, Audard V, Roth SP, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatinbased chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004; 15: 460-6

29) Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005; 200: 845-53

30) Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90 days mortality after resection of hepatic colorectal metastases. J Clin Oncol. 2006; 24: 2065-72

31) Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIR) as first-line treatment for metastatic colorectal cancer. J Clin Oncol. 2007; 25: 1670-6

32) Van Custem E, Nowacki M, Long I, et al. Randomized phase III study of irinotecan and 5FU/FA with or without cetuximab in the first-live treatment of patients with metastatic colorectal cancer the crystal trial. ASCO Annual Meeting. 2007; abst

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp